Nebula Research & Development LLC Cytokinetics Inc Transaction History
Nebula Research & Development LLC
- $1.08 Trillion
- Q1 2025
A detailed history of Nebula Research & Development LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Nebula Research & Development LLC holds 12,165 shares of CYTK stock, worth $436,723. This represents 0.05% of its overall portfolio holdings.
Number of Shares
12,165Holding current value
$436,723% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
399Shares Held
128MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$527 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$425 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$357 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$287 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$218 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.38B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...